

1 **Association between *Helicobacter pylori* infection and incident risk of dementia: the AMI**  
2 **cohort.**

3 **Running title: *H. pylori* and incident dementia: the AMI cohort.**

4

5 **Virgilio Hernández-Ruiz<sup>a\*</sup>, M.D.; Claire Roubaud-Baudron<sup>b,c\*</sup>, M.D., Ph.D.; Hugo Von**  
6 **Campe<sup>a</sup>, M.Sc.; Noelia Retuerto<sup>a</sup>, M.Sc.; Francis Mégraud<sup>c</sup>, M.D.; Catherine Helmer<sup>a</sup>,**  
7 **M.D., Ph.D.; Hélène Amieva<sup>a</sup>, Ph.D.; Karine Pérès<sup>a</sup>, Ph.D.**

8 a. INSERM, Bordeaux Population Health Research Center, UMR 1219, University of  
9 Bordeaux, F-33000, Bordeaux, France.

10 b. CHU Bordeaux, Pôle de Gériatrie Clinique, 33000, Bordeaux, France.

11 c. University of Bordeaux, INSERM, UMR U1312 - BRIC, 33000, Bordeaux, France.

12

13 \*co-first authors

14

15 **Corresponding author**

16 **Karine Pérès, Ph.D.**

17 Bordeaux Population Health Research Center

18 University of Bordeaux, Bordeaux, France

19 karine.peres@u-bordeaux.fr

20 Phone + 33 (0) 557 574 515

21

22 **Word Count: 2119            Tables and Figures: 3**

23

24

25 **Funding Sources:**

26 The AMI project was funded by AGRICA (CAMARCA, CRCCA, CCPMA PREVOYANCE,  
27 CPCEA, AGRI PREVOYANCE), the Mutualité Sociale Agricole (MSA) de Gironde, and the  
28 Caisse Centrale de la MSA. The funding sources had no role in the design, analysis, and data  
29 interpretation, writing, or reporting of the manuscript.

30

31 **KEY POINTS**

- 32 • In a population-based cohort of older farmers in Southwest France, seropositivity to *H.*  
33 *pylori* infection was independently associated with all-cause incident dementia during a  
34 7-year follow-up.
- 35 • After adjustment for numerous dementia risk factors, the observed association was  
36 stronger for Alzheimer’s disease.
- 37 • Despite a decreasing prevalence of *H. pylori* infection in high-income countries (29%  
38 in our study versus 65% reported in a previous epidemiological study conducted in the  
39 same area 15 years ago), a significant association with incident dementia is still  
40 observed.

41

42

43

44

45

46

47 **WHY DOES THIS MATTER?**

48 Infectious diseases are increasingly being considered as potential contributors to the risk of all-  
49 cause dementia. Despite a decreasing prevalence, *H. pylori* infection remains one of the major  
50 causes of chronic gastritis worldwide. In this sense, the results reported in this study provide  
51 evidence of one relevant potentially modifiable risk factor for dementia that may also be of  
52 particular interest in low and middle-income countries where *H. pylori* infection remains  
53 frequent, and where the number of older adults is steadily growing, and the largest dementia  
54 increases are occurring.

55

56

57

58

59

60 **ABSTRACT**

61 **Background:** Chronic infectious diseases are increasingly being considered as potential  
62 contributors to dementia risk. Among those infections, *Helicobacter pylori*, the main cause of  
63 chronic gastritis worldwide, has been suggested. As the prevalence of *H. pylori* infection has  
64 decreased, the main objective of this work was to reconsider the association between *H. pylori*  
65 infection and the risk of incident dementia, including Alzheimer's disease.

66 **Methods:** Prospective cohort of 689 older ( $\geq 65$  years) agricultural workers from Southwest  
67 France. Descriptive and comparative analyses were performed according to *H. pylori* status  
68 determined by serology at baseline. The risk of incident dementia according to *H. pylori* status  
69 over a 7-year follow-up was explored by survival analyses: Kaplan Meier curve and Cox  
70 proportional hazards models.

71 **Results:** Two-hundred (29.0%) participants were *H. pylori* positive at baseline. Compared to  
72 *H. pylori* negative participants, they showed worse cognitive performances at baseline. Eighty-  
73 five incident dementia cases were diagnosed during the follow-up period. After adjustment for  
74 age, sex, education, apolipoprotein  $\epsilon 4$ , and several cardiovascular risk factors, *H. pylori*  
75 remained associated with an increased risk of dementia (HR 1.70, 95% CI, 1.05-2.74). The risk  
76 was stronger for Alzheimer's disease (HR 2.85, 95% CI, 1.58-5.12).

77 **Conclusions:** Despite an observed decrease in *H. pylori* infection prevalence, this study  
78 provides evidence for the association between *H. pylori* infection and dementia. These results  
79 should encourage further research on the mechanisms underlying the contribution of infectious  
80 diseases to pathological brain aging, especially the influence of gut inflammation on the brain.

81 **Abstract word count:** 242 words

82 **Key words:** *H. pylori*, dementia, Alzheimer's disease

## 83 INTRODUCTION

84 Alzheimer's disease (AD) accounts for nearly 80% of dementia cases, and is one of the leading  
85 causes of disability worldwide.<sup>1,2</sup> Besides well-known risk factors (i.e., socioeconomic  
86 conditions, genetics, lifestyle, etc.), several pathophysiological hypotheses have been explored  
87 to explain the disease, including the amyloid cascade and the accumulation of abnormal forms  
88 of various proteins leading to neurodegeneration.<sup>1,3</sup> However, the view considering the disease  
89 as a multifactorial phenomenon to which different mechanisms contribute over time is  
90 commonly accepted.<sup>2</sup>

91 Among those factors, a growing body of evidence focuses on infectious diseases. Either through  
92 common or microorganism-specific mechanisms, some infections could trigger or worsen  
93 neurodegeneration.<sup>4</sup> In the long list of infectious diseases which have been suggested, infection  
94 by *Helicobacter pylori*, a Gram-negative bacillus and the main cause of chronic gastritis  
95 worldwide, is a relevant candidate.<sup>4</sup> As an infection often contracted during childhood, and  
96 mostly asymptomatic, *H. pylori* usually remains undiagnosed along with a low-grade lifelong  
97 chronic inflammatory state, which could participate in extra-digestive manifestations of disease  
98 including neurodegeneration.<sup>5,6</sup>

99 Even though *H. pylori* prevalence has tended to decrease these last decades, cross-sectional  
100 studies hint toward a high prevalence of this infection in older adults with cognitive disorders.<sup>7-</sup>  
101 <sup>9</sup> Likewise, longitudinal studies report different rates of negative cognitive outcomes in *H.*  
102 *pylori* positive individuals or those treated for the infection.<sup>10-12</sup> Therefore, a few population-  
103 based studies have re-evaluated these associations, in particular the risk of incident dementia  
104 but with inconsistent results.<sup>13-15</sup>

105 Given the contrasting results published to date, as well as the prevalence of *H. pylori* infection  
106 in high-income countries which may have decreased these last decades, further epidemiological  
107 research is needed.<sup>9</sup>

108 Therefore, this work investigated the association between *H. pylori* infection and the incidence  
109 of dementia within a prospective cohort of older adults in Southwest France<sup>16</sup> involving a 7-  
110 year follow-up.

111

## 112 **METHODS**

113

### 114 **Population and study design**

115 The participants were recruited from the AMI (Aging Multidisciplinary Investigation) cohort,  
116 an ongoing epidemiological prospective study on aging initiated in 2007 (complete  
117 methodology previously published).<sup>16</sup> At baseline, 1002 retired farmers aged  $\geq 65$  years and  
118 living in Southwest France were randomly recruited from the Farmers Health Insurance System.  
119 Written informed consent was obtained from all participants. The ethics committee of the  
120 University Hospital of Bordeaux approved this research according to the principles of the  
121 Helsinki Declaration.

122 The present study included the 689 participants who agreed to provide blood samples and with  
123 available *H. pylori* serology at baseline.

### 124 **Data Collection and Laboratory Samples**

125 Psychologists conducted standardized at-home evaluations every two to three years (4 waves,  
126 from 2007 – 2015), collecting sociodemographic, environmental, neuropsychological,  
127 functional, and medical information at each wave. Blood samples were collected at baseline,

128 frozen, and stored for ancillary studies. Serological detection of *H. pylori* infection was  
129 performed using a two-step approach. 1) Enzyme-linked immunosorbent assay (BIOHIT *H.*  
130 *pylori* IgG ELISA kit, Biohit Health Care, Ellesmere Port, UK) testing for IgG anti-*H. pylori*  
131 antibodies; identifying an active infection. 2) If negative, a western blot (HELICO BLOT,  
132 Genelabs Diagnostics, Singapore) was performed to detect persistent anti-*H. pylori* antibodies;  
133 accounting-for a past infection. However, serological results from ELISA tests may not reliably  
134 distinguish between active and past infections. Participants were considered as "*H. pylori*  
135 positive" if one of the two tests was positive.

### 136 **Outcome**

137 Comprehensive neuropsychological assessment included global cognitive abilities [Mini  
138 Mental State Examination<sup>17</sup> (MMSE)], episodic memory [Free and Cued Selective Reminder  
139 Test (FCSRT), Grober & Buschke<sup>18</sup>], abstract thinking (WAIS similarities subtest<sup>19</sup>), and  
140 verbal fluency (Isaacs' set test<sup>20</sup>). Afterwards, neuropsychologists selected those participants  
141 with suspected dementia and proposed a visit by a neurologist or a geriatrician for a clinical  
142 examination to confirm the diagnosis and the etiology.

143 Dementia diagnosis relied on a 3-step procedure: 1) Neuropsychological evaluation with a  
144 criteria checklist for dementia using the Diagnostic and Statistical Manual of Mental Disorders,  
145 Third Edition, Revised (DSM-III R); 2) A neurologist or geriatrician reevaluated individuals  
146 who met dementia criteria to confirm or exclude the diagnosis, and 3) An independent  
147 committee of experts reviewed and validated all the diagnoses and their etiology according to  
148 current standards.<sup>16</sup> AD etiology was assigned according to the National Institute of  
149 Neurological and Communication Disorders and Stroke/Alzheimer's Disease and Related  
150 Disorders Association (NINCDS-ADRDA) criteria.<sup>21</sup>

### 151 **Covariates**

152 Sociodemographic variables included age, sex, and educational level (lower defined by less  
153 than 7 years of schooling). Lifestyle-related factors included current or former consumption of  
154 tobacco and alcohol, weight and height allowing body mass index calculation (BMI=weight  
155 (kg)/height (m)<sup>2</sup>). Health-associated variables included chronic diseases (e.g.,  
156 hypercholesterolemia, hypertension, and diabetes), cardiovascular diseases (arterial disease,  
157 chronic heart failure, stroke and coronary disease; assessed from the second wave of data  
158 collection and onwards), and apolipoprotein ε4 (ApoE-ε4) status (at least one allele).  
159 Depressive symptomatology was assessed using the Center for Epidemiologic Studies  
160 Depression (CES-D) scale.<sup>22,23</sup> Functional status was assessed by instrumental activities of  
161 daily living<sup>24</sup> (IADL), basic activities of daily living<sup>25</sup> (ADL), and the Rosow-Breslau scale.<sup>26</sup>  
162 A hierarchical dependency indicator combining the three previous scales was categorized in  
163 increasing levels, as previously published [full independence, mild dependency (mobility  
164 limitation only), moderate dependency (mobility and IADL limitation), and severe dependency  
165 (mobility, IADL, and ADL limitation)].<sup>27</sup>

## 166 **Statistical analysis**

167 A description and comparative analyses of the participants by *H. pylori* infection status were  
168 performed. For quantitative variables, Student's t and Wilcoxon tests were used and for  
169 qualitative variables, the  $\chi^2$  and Fisher tests.

170 Multivariate logistic regression analyses were performed to identify the variables associated  
171 with *H. pylori* infection. The initial model included all factors associated with *H. pylori* in the  
172 univariate analysis at a 20% threshold. Afterwards, a stepwise regression analysis allowed the  
173 identification of factors independently associated with the infection at a 5% threshold.



174 The risk of incident dementia (all type and AD specifically) was explored over a 7-year period  
175 according to *H. pylori* infection status by survival analyses (dementia-free) with two  
176 complementary approaches:

177 1) A Kaplan Meier curve to estimate the survival function (participants without dementia)  
178 in the population, according to the infection status.

179 2) Delayed-entry Cox proportional hazards model to estimate the risk of incident  
180 dementia. Prevalent dementia cases at baseline, participants with no follow-up, with an  
181 undetermined cognitive diagnosis or / and with missing data for the explanatory  
182 variables were excluded. The models were adjusted for the main dementia risk factors  
183 (sex, educational level, ApoE-ε4, cardiovascular diseases, hypercholesterolemia,  
184 hypertension, diabetes, obesity, alcohol and tobacco consumption), and factors found to  
185 be associated with the infection in the logistic regression analyses.

186 Statistical analyses were performed with R Studio (Version 4.0.3).

187

## 188 **RESULTS**

189

### 190 *Participants' characteristics at baseline and comparison according to H. pylori status*

191 The mean age of the 689 participants was 75.8 years (SD 6.4), and 262 (38.0%) were women  
192 (**Table 1**). Two-hundred participants had a positive *H. pylori* serology (29.0%). *H. pylori*  
193 positive participants were more likely to have a low educational level [128 (64.3%) vs 224  
194 (45.8%),  $p < 0.001$ ], age  $\geq 80$  years [64 (32%) vs 119 (24.3%),  $p = 0.038$ ], and lower limb arterial  
195 disease [15 (7.5%) vs 18 (3.7%),  $p = 0.033$ ].

196 *H. pylori* positive participants had a lower MMSE score [24.3 (SD 4.2) vs. 25.5 (SD 3.9),  
197  $p<0.01$ ] and showed worse performances in the other two tests considered (Similarities and  
198 Isaacs set tests). **Supplementary Table 1.** Dementia at inclusion was not different according  
199 to infection status.

200 For the multivariate logistic regression analyses, after excluding the 60 participants with  
201 missing data, a sample of 629 participants was available. **Supplementary Table 2** presents the  
202 initial and final models after stepwise regressions.

203 In the final model (5% threshold), MMSE score  $<24$  at baseline (OR=1.76; 95% CI, 1.15-2.71;  
204  $p=0.009$ ), lower educational level (OR=1.71; 95% CI, 1.15-2.52;  $p=0.007$ ), and age  $\geq 80$  years  
205 (OR=1.49; 95% CI, 1.0-2.21;  $p=0.043$ ) were independently associated with *H. pylori* infection.

#### 206 *Risk of incident dementia according to H. pylori status*

207 Of the 689 participants, 74 prevalent dementia cases were excluded, as well as 45 participants  
208 with no follow-up data, and 1 with an undetermined cognitive diagnosis. Thus, the Kaplan-  
209 Meier curve included 569 participants. Concerning the Cox model, 45 additional participants  
210 were excluded due to missing data for the adjustment variables, resulting in 524 participants.

211 The Kaplan-Meier curves show the probability of dementia-free survival over time from  
212 baseline according to *H. pylori* status. Within the 569 participants, 90 incident dementia cases  
213 were identified during the 7-year follow-up. The dementia risk was significantly lower in  
214 *H. pylori* negative participants (Log-Rank test,  $p=0.031$ ). **Figure 1.**

215 Of the 524 participants included in the Cox model, 144 (27.5%) were *H. pylori* positive. Over  
216 the 7-year follow-up, 85 incident dementia cases were identified, of whom 55 were *H. pylori*  
217 negative, and 30 were positive. In the complete multivariate model, after adjustment for  
218 potential confounders, *H. pylori* infection was independently associated with an increased risk  
219 of dementia (HR 1.70; 95% CI, 1.05-2.74;  $p=0.03$ ). **Table 2.** In the model focusing on AD

220 cases, of the 524 participants considered, 54 developed AD of whom 30 cases were *H. pylori*  
221 negative, and 24 were positive. After adjustment for potential confounders, *H. pylori* remained  
222 independently associated with an increased risk for AD (HR 2.85; 95% CI, 1.58-5.12;  $p < 0.001$ ).

223 **Table 2.**

224

## 225 **DISCUSSION**

226 Based on data from a prospective population-based cohort of retired farmers, this study reports  
227 a prevalence of *H. pylori* of 29%, which is much lower than the 65% reported in another French  
228 cohort (PAQUID), a study conducted in the same area of France nearly 20 years earlier.<sup>14</sup>  
229 Therefore, *H. pylori* prevalence is substantially decreasing in high-income countries, probably  
230 due to an improvement in hygiene standards, as already reported in the literature.<sup>9</sup>

231 Regarding cognition, *H. pylori* status was associated with lower baseline performances as  
232 reported by previous cross-sectional studies.<sup>7,8</sup> Beyond baseline cognitive scores, this study  
233 prospectively examined the risk of incident dementia according to *H. pylori* status. During the  
234 7-year follow-up, *H. pylori*-positive participants had an increased risk of dementia,  
235 independently of various dementia risk factors [HR=1.70], the risk of AD being still stronger  
236 [HR=2.85]. Few longitudinal studies have addressed this issue.<sup>10,11</sup> For instance, retrospective  
237 analyses from US-based surveys reported an association between *H. pylori* seropositivity with  
238 incident all-cause dementia.<sup>13,28</sup> The PAQUID study reported similar results (HR 1.46; 95% CI,  
239 1.01-2.11)<sup>14</sup> while a population-based cohort from the Netherlands with a 13-year follow-up  
240 did not find an association between *H. pylori* seropositivity and dementia risk (HR 1.03; 95%  
241 CI, 0.86-1.22).<sup>15</sup> However, potential implications of evaluating this association without longer-  
242 lasting antibodies (i.e., case underestimation) have been discussed elsewhere.<sup>29</sup>

243 Concerning the potential mechanisms linking *H. pylori* to an increased risk of dementia, diverse  
244 pathways have been proposed. *H. pylori* infection is indeed a source of gastric inflammation,  
245 but also of chronic low-grade systemic inflammation which, in turn, may activate neuro-  
246 inflammatory pathways that end-up participating in neurodegeneration.<sup>5,6</sup> Likewise, a vascular  
247 hypothesis suggests that the vitamin B12 deficiency induced by the disease may lead to hyper-  
248 homocysteinemia, a known risk factor for cardiovascular disease and AD.<sup>30</sup> Furthermore, recent  
249 studies discuss the role of the "gut-brain" axis, and a bidirectional communication between the  
250 enteric and central nervous systems, which can be altered by *H. pylori*.<sup>31</sup>

251 Finally, the increased incidence of dementia observed in older adults with *H. pylori* infection  
252 may not be explained by a single phenomenon. The infection itself could reflect a series of  
253 conditions (childhood, hygiene, nutritional, economic, etc.) that also influence dementia risk.  
254 Improvement of those conditions over time may explain the lower seroprevalence observed in  
255 this cohort compared to another French study.<sup>14</sup> Nonetheless, despite this decreasing  
256 prevalence, the previously reported association with dementia and AD is maintained.<sup>14</sup> Further  
257 studies are needed to determine whether *H. pylori* infection is related to dementia by inducing  
258 lifelong gastritis or because it is a marker of poor socioeconomic conditions during childhood.

259 The methodological strengths of this study should be highlighted, such as the robust clinical  
260 diagnosis of dementia, the 7-year follow-up, the availability of relevant variables used for  
261 statistical adjustment, as well as the detection of longer-lasting antibodies against *H. pylori*.  
262 Likewise, the findings may also be of particular interest to low-and middle-income countries  
263 where *H. pylori* infection remains high and where the biggest increases in the population of  
264 older adults and dementia are occurring. Our study also has limitations. The study sample is  
265 relatively small, selection bias cannot be entirely excluded (participants who refused blood  
266 sampling), nor unmeasured residual confounding, as in other observational epidemiological  
267 studies. Concerning the serological diagnosis, ELISA results may not reliably distinguish active

268 and former infections. Finally, the sample is not representative of the general population, as it  
269 consists of agricultural workers. Inherent factors of living in a rural environment could have an  
270 influence on both *H. pylori* infection and dementia.

271 In conclusion, while the prevalence of *H. pylori* infection is decreasing, this study found that  
272 the infection was still associated with an increased risk of dementia, particularly AD. Therefore,  
273 this study adds to the growing evidence of the contribution that infectious diseases may have  
274 on the development of neurodegenerative diseases.

275

276 **ACKNOWLEDGMENTS**

277 **Conflict of Interest**

278 The authors have no financial/personal conflict of interest to disclose.

279 **Authors' contribution**

280 VH, CR, HA, and KP designed, and drafted the manuscript, interpreted the data, and directly  
281 accessed and verified the underlying data reported in the manuscript. HVC, FM and CH  
282 contributed to the critical analysis, and data interpretation. NR performed statistical analyses.

283 All authors meet the criteria for authorship stated in the Uniform Requirements for  
284 Manuscripts Submitted to Biomedical Journals.

285 **Funding / Sponsor's Role**

286 The AMI project was funded by AGRICA (CAMARCA, CRCCA, CCPMA PREVOYANCE,  
287 CPCEA, AGRI PREVOYANCE), the Mutualité Sociale Agricole (MSA) de Gironde, and the  
288 Caisse Centrale de la MSA. The funding source had no role in the design, analysis, and data  
289 interpretation, writing, or reporting of the manuscript.

290 VHR was supported by the National Council of Humanities, Science and Technology  
291 (CONAHCYT) in Mexico.

292 **Data Sharing**

293 The dataset presented in this article is not readily available as it is property of the University of  
294 Bordeaux. Requests to access the dataset should be directed to: Karine Pérès, Ph.D.  
295 [karine.peres@u-bordeaux.fr](mailto:karine.peres@u-bordeaux.fr)

296

## REFERENCES

- 297  
298  
299 1. Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. *Nat Rev Dis Primers*.  
300 May 13 2021;7(1):33. doi:10.1038/s41572-021-00269-y.
- 301 2. Montero-Odasso M, Ismail Z, Livingston G. One third of dementia cases can be  
302 prevented within the next 25 years by tackling risk factors. The case "for" and "against".  
303 *Alzheimers Res Ther*. Jul 8 2020;12(1):81. doi:10.1186/s13195-020-00646-x.
- 304 3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*.  
305 Apr 10 1992;256(5054):184-5. doi:10.1126/science.1566067.
- 306 4. Hernandez-Ruiz V, Letenneur L, Fülöp T, et al. Infectious diseases and cognition: do  
307 we have to worry? *Neurol Sci*. Nov 2022;43(11):6215-6224. doi:10.1007/s10072-022-06280-  
308 9.
- 309 5. Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M.  
310 *Helicobacter pylori* and extragastric diseases: A review. *World J Gastroenterol*. Aug 7  
311 2018;24(29):3204-3221. doi:10.3748/wjg.v24.i29.3204.
- 312 6. Baj J, Forma A, Flieger W, et al. *Helicobacter pylori* Infection and Extragastric  
313 Diseases-A Focus on the Central Nervous System. *Cells*. Aug 25  
314 2021;10(9)doi:10.3390/cells10092191.
- 315 7. Han ML, Chen JH, Tsai MK, et al. Association between *Helicobacter pylori* infection  
316 and cognitive impairment in the elderly. *J Formos Med Assoc*. Nov 2018;117(11):994-1002.  
317 doi:10.1016/j.jfma.2017.11.005.
- 318 8. Rezvani F, Sayadnasiri M, Rezaei O. The study of memory and executive dysfunction  
319 in patients infected with *Helicobacter pylori*. *Neurological Research*. 2017/11/02  
320 2017;39(11):953-958. doi:10.1080/01616412.2017.1363349.
- 321 9. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of  
322 *Helicobacter pylori* infection between 1980 and 2022: a systematic review and meta-analysis.

323 *The lancet Gastroenterology & hepatology*. Jun 2023;8(6):553-564. doi:10.1016/s2468-  
324 1253(23)00070-5.

325 10. Wright CB, Gardener H, Dong C, et al. Infectious Burden and Cognitive Decline in  
326 the Northern Manhattan Study. *J Am Geriatr Soc*. Aug 2015;63(8):1540-5.  
327 doi:10.1111/jgs.13557.

328 11. Cárdenas VM, Boller F, Román GC. Helicobacter pylori, Vascular Risk Factors and  
329 Cognition in U.S. Older Adults. *Brain Sci*. Dec 12 2019;9(12)doi:10.3390/brainsci9120370.

330 12. Chang YP, Chiu GF, Kuo FC, et al. Eradication of Helicobacter pylori Is Associated  
331 with the Progression of Dementia: A Population-Based Study. *Gastroenterol Res Pract*.  
332 2013;2013:175729. doi:10.1155/2013/175729.

333 13. Beydoun MA, Beydoun HA, Elbejjani M, Dore GA, Zonderman AB. Helicobacter  
334 pylori seropositivity and its association with incident all-cause and Alzheimer's disease  
335 dementia in large national surveys. *Alzheimers Dement*. Sep 2018;14(9):1148-1158.  
336 doi:10.1016/j.jalz.2018.04.009.

337 14. Roubaud Baudron C, Letenneur L, Langlais A, et al. Does Helicobacter pylori  
338 infection increase incidence of dementia? The Personnes Agées QUID Study. *J Am Geriatr*  
339 *Soc*. Jan 2013;61(1):74-8. doi:10.1111/jgs.12065.

340 15. Fani L, Wolters FJ, Ikram MK, et al. Helicobacter pylori and the risk of dementia: A  
341 population-based study. *Alzheimers Dement*. Oct 2018;14(10):1377-1382.  
342 doi:10.1016/j.jalz.2018.05.005.

343 16. Pérès K, Matharan F, Allard M, et al. Health and aging in elderly farmers: the AMI  
344 cohort. *BMC Public Health*. 2012/07/27 2012;12(1):558. doi:10.1186/1471-2458-12-558.

345 17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for  
346 grading the cognitive state of patients for the clinician. *J Psychiatr Res*. Nov 1975;12(3):189-  
347 98. doi:10.1016/0022-3956(75)90026-6.



- 348 18. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by  
349 memory testing. *Neurology*. Jun 1988;38(6):900-3. doi:10.1212/wnl.38.6.900.
- 350 19. Kaufman AS. Test Review: Wechsler, D. Manual for the Wechsler Adult Intelligence  
351 Scale, Revised. New York: Psychological Corporation, 1981. *Journal of Psychoeducational*  
352 *Assessment*. 1983/09/01 1983;1(3):309-313. doi:10.1177/073428298300100310.
- 353 20. Isaacs B, Akhtar AJ. The set test: a rapid test of mental function in old people. *Age*  
354 *Ageing*. Nov 1972;1(4):222-6. doi:10.1093/ageing/1.4.222.
- 355 21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical  
356 diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the  
357 auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.  
358 *Neurology*. Jul 1984;34(7):939-44. doi:10.1212/wnl.34.7.939.
- 359 22. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the  
360 General Population. *Applied Psychological Measurement*. 1977/06/01 1977;1(3):385-401.  
361 doi:10.1177/014662167700100306.
- 362 23. Fuhrer R, Rouillon F. La version française de l'échelle CES-D (Center for  
363 Epidemiologic Studies-Depression Scale). Description et traduction de l'échelle  
364 d'autoévaluation. *Psychiatry and Psychobiology*. 1989;4(3):163-166.  
365 doi:10.1017/S0767399X00001590.
- 366 24. Lawton MP, Brody EM. Assessment of older people: self-maintaining and  
367 instrumental activities of daily living. *Gerontologist*. Autumn 1969;9(3):179-86.
- 368 25. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of  
369 ADL. *Gerontologist*. Spring 1970;10(1):20-30. doi:10.1093/geront/10.1\_part\_1.20.
- 370 26. Rosow I, Breslau N. A Guttman health scale for the aged. *Journal of gerontology*. Oct  
371 1966;21(4):556-9. doi:10.1093/geronj/21.4.556.

- 372 27. Barberger-Gateau P, Rainville C, Letenneur L, Dartigues J-F. A hierarchical model of  
373 domains of disablement in the elderly: a longitudinal approach. *Disability and rehabilitation*.  
374 2000;22(7):308-317.
- 375 28. Beydoun MA, Beydoun HA, Shroff MR, Kitner-Triolo MH, Zonderman AB.  
376 *Helicobacter pylori* seropositivity and cognitive performance among US adults: evidence  
377 from a large national survey. *Psychosom Med*. Jun 2013;75(5):486-96.  
378 doi:10.1097/PSY.0b013e31829108c3.
- 379 29. Roubaud-Baudron C, Mégraud F, Salles N, Dartigues JF, Letenneur L. Detecting both  
380 current and prior *Helicobacter pylori* infection is important to assess its impact on dementia.  
381 *Alzheimers Dement*. May 2019;15(5):721-722. doi:10.1016/j.jalz.2018.12.020.
- 382 30. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for  
383 dementia and Alzheimer's disease. *N Engl J Med*. Feb 14 2002;346(7):476-83.  
384 doi:10.1056/NEJMoa011613.
- 385 31. Kountouras J, Zavos C, Polyzos SA, Deretzi G. The gut-brain axis: interactions  
386 between *Helicobacter pylori* and enteric and central nervous systems. *Ann Gastroenterol*. Oct-  
387 Dec 2015;28(4):506.
- 388
- 389

390 **Table 1. Characteristics of the population at baseline, and comparisons according to their**  
 391 ***Helicobacter pylori* serology**

<b>Characteristics</b>	<b>Total (N=689)</b>	<b><i>H. pylori</i> positive (N=200)</b>	<b><i>H. pylori</i> negative (N=489)</b>	<b><i>P</i>-value</b>
<b>Age, mean (SD)</b>	75.8 (6.4)	76.2 (6.8)	75.6 (6.3)	0.270
<b>Age ≥ 80, n (%)</b>	183 (26.6)	64 (32.0)	119 (24.3)	0.038
<b>Women, n (%)</b>	262 (38.0)	76 (38.0)	186 (38.0)	0.992
<b>Low educational level, n (%)</b>	352 (51.2)	128 (64.3)	224 (45.8)	<.001
<b>Obesity (BMI ≥30), n (%)</b>	182 (27.0)	48 (24.9)	134 (27.9)	0.429
<b>Hypertension, n (%)</b>	477 (69.2)	131 (65.5)	346 (70.8)	0.174
<b>Diabetes, n (%)</b>	108 (15.7)	34 (17.0)	74 (15.1)	0.540
<b>Arterial disease (lower limbs), n (%)</b>	33 (4.8)	15 (7.5)	18 (3.7)	0.033
<b>Heart failure, n (%)</b>	85 (12.3)	23 (11.5)	62 (12.7)	0.669
<b>Stroke, n (%)</b>	18 (2.6)	8 (4.0)	10 (2.0)	0.144
<b>Coronary disease, n (%)</b>	77 (11.2)	24 (12.0)	53 (10.8)	0.660
<b>Apolipoprotein ε4 (at least one allele), n (%)</b>	112 (17.5)	32 (17.4)	80 (17.5)	0.972
<b>Hypercholesterolemia, n (%)</b>	351 (50.9)	94 (47.0)	257 (52.6)	0.185
<b>Tobacco, n (%)</b>				0.897
Stopped for > 6 months	209 (30.9)	63 (32.1)	146 (30.4)	
Active or stopped for < 6 months	24 (3.6)	7 (3.6)	17 (3.5)	
<b>Hierarchic dependence indicator, n (%)</b>				0.111
Full independence	239 (36.1)	61 (31.8)	178 (37.8)	
Slight dependence	279 (42.1)	78 (40.6)	201 (42.7)	
Moderate dependence	105 (15.8)	40 (20.8)	65 (13.8)	
Severe dependence	40 (6.0)	13 (6.8)	27 (5.7)	
<b>Depressive symptoms – CESD, n (%)</b>	81 (12.7)	28 (15.5)	53 (11.6)	0.182

392 SD: Standard Deviation, BMI: Body Mass Index

393

394

395

396

397 **Table 2. Longitudinal association between *Helicobacter pylori* and incident dementia: delayed-**  
 398 **entry Cox model**

399  
 400  
 401

Characteristics	All types of dementia N=85 incident cases			Alzheimer's disease N=54 incident cases		
	Hazard Ratio	95% CI	P-value	Hazard Ratio	95% CI	P-value
<i>H. pylori</i> seropositivity	1.70	1.05-2.74	0.030	2.85	1.58-5.12	<.001
<b>Women</b>	0.86	0.48-1.55	0.617	0.48	0.23-0.98	0.044
<b>Low educational level</b>	1.26	0.78-2.03	0.340	0.85	0.46-1.55	0.586
<b>Apolipoprotein ε4</b>	1.61	0.95-2.74	0.077	1.54	0.79-2.99	0.202
<b>Coronary disease</b>	0.76	0.36-1.61	0.469	0.73	0.30-1.78	0.485
<b>Arterial disease (lower limbs)</b>	0.44	0.15-1.34	0.149	0.68	0.21-2.18	0.518
<b>Heart failure</b>	0.62	0.30-1.26	0.186	0.59	0.25-1.42	0.238
<b>Stroke</b>	1.96	0.55-6.90	0.297	0.48	0.06-4.11	0.506
<b>Hypercholesterolemia</b>	1.03	0.63-1.67	0.910	1.79	0.96-3.33	0.067
<b>Hypertension</b>	0.98	0.60-1.60	0.940	0.96	0.51-1.81	0.910
<b>Diabetes</b>	1.54	0.87-2.73	0.136	1.38	0.67-2.85	0.385
<b>Obesity</b>	0.78	0.44-1.35	0.372	0.89	0.44-1.80	0.749
<b>Alcohol</b>	0.77	0.46-1.28	0.307	0.54	0.29-1.03	0.061
<b>Tobacco</b>			0.046			0.056
Former smoker	1.51	0.86-2.66	0.153	0.94	0.46-1.90	0.854
Current smoker	3.24	1.21-8.69	0.020	3.78	1.21-11.82	0.022

402 CI: Confidence interval

403  
 404

405 **Figure 1. Kaplan Meier curve estimating dementia-free survival in the population**  
406 **according to the infection status.**

407

408

409

